{{Rsnum
|rsid=11568563
|Gene=SLCO1A2
|Chromosome=12
|position=21304500
|Orientation=plus
|GMAF=0.03352
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
|Gene_s=SLCO1A2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 0.0 | 0.0 | 0.0
| HCB | 100.0 | 0.0 | 0.0
| JPT | 100.0 | 0.0 | 0.0
| YRI | 0.0 | 0.0 | 0.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 100.0 | 0.0 | 0.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs11568563
|Name_s=SLCO1A2: E172D
|Gene_s=SLCO1A2
|Feature=Exon/NonSyn
|Evidence=PubMed ID:19940846
|Annotation=Reduced uptake of estrone sulfate and methotrexate in oocytes
|Drugs=conjugated estrogens; methotrexate
|Drug Classes=
|Diseases=
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA165111595
}}

{{PMID Auto GWAS
|PMID=21685912
|Trait=None
|Title=Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy.
|RiskAllele=
|Pval=7E-8
|OR=1.4700
|ORtxt=[1.28-1.69]
|OA=1
}}

{{GET Evidence
|gene=SLCO1A2
|aa_change=Glu172Asp
|aa_change_short=E172D
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs11568563
|overall_frequency_n=457
|overall_frequency_d=10758
|overall_frequency=0.04248
|n_genomes=3
|n_genomes_annotated=0
|n_haplomes=3
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|pph2_score=0.997
|nblosum100=-2
|autoscore=4
|webscore=N
|n_web_uneval=10
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}